Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRST-NEC: durvalumab plus etoposide and platinum in first-line pulmonary LCNEC
2023-506590-35-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Jun 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, etoposide, carboplatin and cisplatin in Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC), sponsored by Centre Léon Bérard. Primary endpoint: Progression-Free Rate at 12 months. Planned start Jun 2024; status: authorised.
02
Drugs
durvalumabetoposidecarboplatincisplatin
03
Conditions
Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)
Beyond the preview
Go deeper on 2023-506590-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506590-35-00.